HLX26

DRUG4 trials

Sponsors

Shanghai Henlius Biotech

Conditions

Adult Solid TumorColorectal Cancer MetastaticLymphomaNSCLC Stage IVSolid Tumor, Adult

Phase 1

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma

CompletedNCT05078593

Shanghai Henlius BiotechLymphoma, Solid Tumor, Adult

Start: 2021-10-11End: 2023-08-18Updated: 2024-02-23

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

CompletedNCT05400265

Shanghai Henlius BiotechAdult Solid Tumor

Start: 2022-07-26End: 2024-01-31Updated: 2024-02-06

Phase 2

Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC

TerminatedNCT05584137

Shanghai Henlius BiotechColorectal Cancer Metastatic

Start: 2023-06-15End: 2023-12-31Updated: 2024-10-15

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

Active, not recruitingNCT05787613

Shanghai Henlius BiotechNSCLC Stage IV

Start: 2023-07-10End: 2027-07-31Target: 132Updated: 2025-08-06

Related Papers

Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors.

2026-01-15

Safety, tolerability, and pharmacokinetics of HLX26 (an anti-LAG3 antibody) in patients with advanced or metastatic solid tumors or lymphomas.

Journal of Clinical Oncology2023-06-01